본문 바로가기
KERD
논문KCI 등재

Opioid-induced constipation: a narrative review of therapeutic options in clinical management

Kordula Lang-Illievich|Helmar Bornemann-Cimenti
대한통증학회 (The Korean Pain Society)|2019.04|The Korean Journal of Pain|제32권 제2호|pp. 69-78|DOI 10.3344/kjp.2019.32.2.69

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

.IncidenceExercisePain managementQuality of life.ConstipationHabitsDietary fiberEnemaLaxativesNarcotic antagonistsOpioid analgesicsPharmaceutical preparations

초록

Pain therapy often entails gastrointestinal adverse events. While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies greatly from 15% to as high as 81%. This can lead to a significant impairment in quality of life, often resulting in discontinuation of opioid therapy. In this regard, a good doctor-patient relationship is especially pivotal when initiating opioid therapy. In addition to a detailed history of bowel habits, patient education regarding the possible gastrointestinal side effects of the drugs is crucial. In addition, the bowel function must be regularly evaluated for the entire duration of treatment with opioids. Furthermore, if the patient has preexisting constipation that is well under control, continuation of that treatment is important. In the absence of such history, general recommendations should include sufficient fluid intake, physical activity, and regular intake of dietary fiber. In patients of OIC with ongoing opioid therapy, the necessity of opioid use should be critically reevaluated in terms of an with acceptable quality of life, particularly in cases of non-cancer pain. If opioids must be continued, lowering the dose may help, as well as changing the type of opioid. If these measures do not suffice, the next step for persistent OIC is the administration of laxatives. If these are ineffective as well, treatment with peripherally active -opioid receptor antagonists should be considered. Enemas and irrigation are emergency measures, often used as a last resort.

Abstract

Pain therapy often entails gastrointestinal adverse events. While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies greatly from 15% to as high as 81%. This can lead to a significant impairment in quality of life, often resulting in discontinuation of opioid therapy. In this regard, a good doctor-patient relationship is especially pivotal when initiating opioid therapy. In addition to a detailed history of bowel habits, patient education regarding the possible gastrointestinal side effects of the drugs is crucial. In addition, the bowel function must be regularly evaluated for the entire duration of treatment with opioids. Furthermore, if the patient has preexisting constipation that is well under control, continuation of that treatment is important. In the absence of such history, general recommendations should include sufficient fluid intake, physical activity, and regular intake of dietary fiber. In patients of OIC with ongoing opioid therapy, the necessity of opioid use should be critically reevaluated in terms of an with acceptable quality of life, particularly in cases of non-cancer pain. If opioids must be continued, lowering the dose may help, as well as changing the type of opioid. If these measures do not suffice, the next step for persistent OIC is the administration of laxatives. If these are ineffective as well, treatment with peripherally active -opioid receptor antagonists should be considered. Enemas and irrigation are emergency measures, often used as a last resort.

참고문헌 (82)

  1. Häuser W, "Long-term opioid therapy in c hronic n oncancer p ain : a systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks", Schmerz, 29, pp.96~108 (2015)
  2. Kalso E, "O pioids in chronic non-cancer pain : systematic review of efficacy and safety", Pain, 112, pp.372~380 (2004)
  3. Søndergaard J, "Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy : a nationwide register-based cohort study in Denmark", Scand J Pain, 15, pp.83~90 (2017)
  4. Camilleri M, "Opioid-induced constipation : challenges and therapeutic opportunities", Am J Gastroenterol, 106, pp.835~842 (2011)
  5. Ketw aroo GA, "O pioid-induced bow el dysfunction", Curr Gastroenterol Rep, 15, pp.344~ (2013)
  6. Nelson AD, "Chronic opioid induced constipation in patients with nonmalignant pain : challenges and opportunities", Therap Adv Gastroenterol, 8, pp.206~220 (2015)
  7. Tafelski S, "Incidence of constipation in patients with outpatient opioid therapy", Schmerz, 30, pp.158~165 (2016)[DOI]
  8. Gaertner J, "Definitions and outcome measures of clinical trials regarding opioid-induced constipation : a systematic review", J Clin Gastroenterol, 49, pp.9~16 (2015)
  9. Brenner DM, "Opioid-related constipation in patients with non-cancer pain syndromes : a review of evidence-based therapies and justification for a change in nomenclature", Curr Gastroenterol Rep, 19, pp.12~ (2017)
  10. Ducrotté P, "Prevalence and clinical features of opioid-induced constipation in the general population : a French study of 15, 000 individuals", United European Gastroenterol J, 5, pp.588~600 (2017)
  11. Argoff CE, "Consensus recommendations on initiating prescription therapies for opioid-induced constipation", Pain Med, 16, pp.2324~2337 (2015)
  12. Frank L, "Psychometric validation of a constipation symptom assessment questionnaire", Scand J Gastroenterol, 34, pp.870~877 (1999)
  13. Marquis P, "Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire", Scand J Gastroenterol, 40, pp.540~551 (2005)
  14. Coyne KS, "Assessment of a stool symptom screener and understanding the opioidinduced constipation symptom experience", Patient, 8, pp.317~327 (2015)
  15. Rentz AM, "Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries", Curr Med Res Opin, 27, pp.35~44 (2011)
  16. Camilleri M, "Validation of a bowel function diary for assessing opioid-induced constipation", Am J Gastroenterol, 106, pp.497~506 (2011)
  17. Sobczak M, "Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract : current concepts and future perspectives", J Gastroenterol, 49, pp.24~45 (2014)
  18. Brock C, "Opioid-induced bowel dysfunction : pathophysiology and management", Drugs, 72, pp.1847~1865 (2012)
  19. Dorn S, "Opioid-induced b ow el dysfunction : epidemiology, pathophysiology, diagnosis, and initial therapeutic approach", Am J Gastroenterol Suppl, 2, pp.31~37 (2014)
  20. Galligan JJ, "Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat", J Pharmacol Exp Ther, 226, pp.356~361 (1983)
  21. Finco G, "Is target opioid therapy within sight?", Minerva Anestesiol, 78, pp.462~472 (2012)
  22. Vallerand AH, "Analysis of patient-provider interactions regarding the burden and treatment of opioid-induced constipation in adults with chronic noncancer pain", Pain Med (2018)[DOI]
  23. Müller-Lissner SA, "Myths and misconceptions about chronic constipation", Am J Gastroenterol, 100, pp.232~242 (2005)
  24. De Schryver AM, "Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation", Scand J Gastroenterol, 40, pp.422~429 (2005)
  25. Andresen V, "S2k guideline for chronic constipation : definition, pathophysiology, diagnosis and therapy", Z Gastroenterol, 51, pp.651~672 (2013)
  26. Suares NC, "Systematic review : the effects of fibre in the management of chronic idiopathic constipation", Aliment Pharmacol Ther, 33, pp.895~901 (2011)
  27. Ruston T, "Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation : a systematic review", Can Oncol Nurs J, 23, pp.236~246 (2013)
  28. Rauck RL, "Opioid-induced constipation survey in patients with chronic noncancer pain", Pain Pract, 17, pp.329~335 (2017)
  29. Caraceni A, "Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC", Lancet Oncol, 13, pp.e58~e68 (2012)
  30. Manchikanti L, "American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2--guidance", Pain Physician, 15(3 Suppl), pp.S67~S116 (2012)
  31. Freedman MD, "Tolerance and efficacy of polyethylene glycol 3350", electrolyte solution versus lactulose in relieving opiate induced constipation : a double-blinded placebo-controlled trial, 1997, pp.37, 904~907
  32. Müller-Lissner S, "Myth about causes and treatment of constipation", MMW Fortschr Med, 155, pp.56~57 (2013)
  33. Leppert W, "Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction", Drug Des Devel Ther, 9, pp.2215~2231 (2015)
  34. Knotkova H, "Opioid rotation : the science and the limitations of the equianalgesic dose table", J Pain Symptom Manage, 38, pp.426~439 (2009)
  35. Michaeli K, "Opioid dose ratios in pain therapy : an evidence-based contemplation", Eur J Anaesthesiol, 27, pp.25~26 (2010)
  36. Mercadante S, "Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit", J Pain Symptom Manage, 37, pp.632~641 (2009)
  37. Allan L, "Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain", Spine (Phila Pa 1976), 30, pp.2484~2490 (2005)
  38. Tassinari D, "Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine : a meta-analysis and systematic review of the literature", J Palliat Med, 11, pp.492~501 (2008)
  39. Ahn JS, "Transdermal buprenorphine and fentanyl patches in cancer pain : a network systematic review", J Pain Res, 10, pp.1963~1972 (2017)
  40. Hadley G, "Transdermal fentanyl for cancer pain", Cochrane Database Syst Rev, (10), pp.CD010270~ (2013)
  41. 장은정, "Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?", The Korean Journal of Pain, 29(3), pp.153~157 (2016), 대한통증학회
  42. Tzschentke TM, "(-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride(tapentadol HCl) : a novel mu-opioid receptor agonist", norepinephrine reuptake inhibitor with broad-spectrum analgesic properties, 2007, pp.323, 265~276
  43. Mercadante S, "The role of tapentadol as a strong opioid in cancer pain management : a systematic and critical review", Curr Med Res Opin, 33, pp.1965~1969 (2017)
  44. Lange B, "Efficacy and safety of tapentadol prolonged release for moderateto-severe chronic osteoarthritis knee pain : a pooled analysis of two double-blind, randomized, placebo-and oxycodone controlled release-controlled studies", Curr Med Res Opin, 33, pp.1413~1422 (2017)
  45. Xiao JP, "Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain : a systematic review and metaanalysis", Pain Med, 18, pp.14~24 (2017)
  46. Leppert W, "Oxycodone", naloxone in the management of patients w ith pain a nd o pioid-induced bow el d ysfunction, 2014, pp.15, 124~135
  47. Bujedo BM, "Treatment of failed back surgery syndrome in a forty-three-year-old man with high-dose oxycodone", naloxone, 2015, pp.5, e21009~
  48. Koopmans G, "Fixed ratio(2 : 1)prolonged-release oxycodone", naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives, 2014, pp.30, 2389~2396
  49. Morlion BJ, "Oral prolonged-release oxycodone", naloxone for managing pain and opioid-induced constipation : a review of the evidence, 2018, pp.18, 647~665
  50. Rychlik R, "Pain management - current issues and opinions", pp.307~320 (2012), Intech
  51. Ueberall MA, "Efficacy and tolerability balance of oxycodone", naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations, 2016, pp.9, 1001~1020
  52. Poulsen JL, "Prolonged-release oxycodone", naloxone improves anal sphincter relaxation compared to oxycodone plus macrogol 3350, 2017, pp.62, 3156~3166
  53. Fruhwald S, "Gastrointestinal motility in acute illness", Wien Klin Wochenschr, 120, pp.6~17 (2008)
  54. Papa P, "Neostigmine for the treatment of gastrointestinal atony : a report of one case", J Palliat Med, 14, pp.1270~1273 (2011)
  55. Christoph Klivinyi, "Pain medication and long QT syndrome", The Korean Journal of Pain, 31(1), pp.3~9 (2018), 대한통증학회
  56. Chapman H, "The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+channel and the common T897 polymorph", Eur J Pharmacol, 554, pp.98~105 (2007)
  57. Ford AC, "Efficacy of pharmacological therapies for the treatment of opioidinduced constipation : systematic review and meta-analysis", Am J Gastroenterol, 108, pp.1566~1574 (2013)[DOI]
  58. Sloots CE, "Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation", Dig Dis Sci, 55, pp.2912~2921 (2010)
  59. Holder RM, "Novel oral therapies for opioid-induced bowel dysfunction in patients with chronic noncancer pain", Pharmacotherapy, 36, pp.287~299 (2016)
  60. Cuppoletti J, "Methadone but not morphine inhibits lubiprostone-stimulated Cl-currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl-currents", Cell Biochem Biophys, 66, pp.53~63 (2013)
  61. Jamal MM, "A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain", Am J Gastroenterol, 110, pp.725~732 (2015)
  62. Cryer B, "A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain", Pain Med, 15, pp.1825~1834 (2014)
  63. Spierings EL, "Efficacy and safety of lubiprostone in patients with opioid-induced constipation : phase 3 study results and pooled analysis of the effect of concomitant methadone use on clinical outcomes", Pain Med, 19, pp.1184~1194 (2018)
  64. Zacny JP, "Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers", Psychopharmacology (Berl), 232, pp.63~73 (2015)
  65. Sridharan K, "Drugs for treating opioid-induced constipation : a mixed treatment comparison network meta-analysis of randomized controlled clinical trials", J Pain Symptom Manage, 55, pp.468~479 (2018)
  66. Jagla C, "Peripheral opioid receptor blockade increases postoperative morphine demands : a randomized, double-blind, placebo-controlled trial", Pain, 155, pp.2056~2062 (2014)
  67. Chey WD, "Naloxegol for opioid-induced constipation in patients with noncancer pain", N Engl J Med, 370, pp.2387~2396 (2014)
  68. Webster L, "A phase 2, double-blind, randomized, placebocontrolled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioidinduced constipation", Pain, 154, pp.1542~1550 (2013)
  69. Bull J, "Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation : results of a randomized, placebo-controlled study and open-label extension", J Palliat Med, 18, pp.593~600 (2015)
  70. Nalamachu S, "Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use", J Opioid Manag, 14, pp.211~221 (2018)
  71. Irving G, "A randomized, placebo-controlled phase 3 trial(Study SB-767905", 013)of alvimopan for opioidinduced bowel dysfunction in patients with non-cancer pain, 2011, pp.12, 175~184
  72. Jansen JP, "A randomized, placebo-controlled phase 3 trial(Study SB-767905", 012)of alvimopan for opioidinduced bowel dysfunction in patients with non-cancer pain, 2011, pp.12, 185~193
  73. Gyawali B, "Opioid-induced constipation", Scand J Gastroenterol, 50, pp.1331~1338 (2015)
  74. Markham A, "Naldemedine : first global approval", Drugs, 77, pp.923~927 (2017)
  75. Hale M, "Naldemedine versus placebo for opioid-induced constipation(COMPOSE-1 and COMPOSE-2) : two multicentre, phase 3, double-blind, randomised, parallel-group trials", Lancet Gastroenterol Hepatol, 2, pp.555~564 (2017)
  76. Webster LR, "A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain", Pain Med, 18, pp.2350~2360 (2017)
  77. Katakami N, "Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer", J Clin Oncol, 35, pp.3859~3866 (2017)
  78. Katakami N, "Phase IIb, randomized, double-blind, placebocontrolled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer", J Clin Oncol, 35, pp.1921~1928 (2017)
  79. Murphy JA, "Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain", Ann Pharmacother, 52, pp.370~379 (2018)
  80. Bove A, "Consensus statement AIGO", SICCR diagnosis and treatment of chronic constipation and obstructed defecation(part II : treatment), 2012, pp.18, 4994~5013
  81. Müller-Lissner S, "Opioid-induced constipation and bowel dysfunction : a clinical guideline", Pain Med, 18, pp.1837~1863 (2017)
  82. Drewes AM, "Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group", Scand J Pain, 11, pp.111~122 (2016)

관련 논문AI추천

암환자의 마약성 진통제 유발성 변비에 대한 예방적 완하제 사용 및 복약순응도 평가박지언, 변정인, 손인자, 이혜숙, 정선회한국병원약사회 · 병원약사회지2011 · 제28권 제2호만성 비암성 통증 환자의 아편유사제 사용강웅구, 윤동욱대한신경정신의학회 · 신경정신의학2019 · 제58권 제3호Chronic Constipation in the Elderly Patient: Updates in Evaluation and ManagementAfif Yaccob, Amir Mari, Fadi Abu Baker, Hana Amara, Mahmud Mahamid대한가정의학회 · Korean Journal of Family Medicine2020 · 제41권 제3호Opioid Pharmacotherapy for Chronic Noncancer Pain: The American ExperienceC. Richard Chapman대한통증학회 · The Korean Journal of Pain2013 · 제26권 제1호Actual situation and prescribing patterns of opioids by pain physicians in South Korea김정은, Hey Ran Choi, Jae Hun Jeong, Jae Hun Kim, Ji Yeon Kim, Min Jung Kim, Min Ki Lee, Sung Jun Hong, Sun Kyung Park, Yun Hee Lim대한통증학회 · The Korean Journal of Pain2022 · 제35권 제4호Updated guidelines for prescribing opioids to treat patients with chronic non-cancer pain in Korea: developed by committee on hospice and palliative care of the Korean Pain SocietyEun Joo Choi, Eunsoo Kim, Hyuckgoo Kim, Jun-Mo Park, Minsoo Kim, Seong-Soo Choi, Sun Kyung Park, Woong Mo Kim대한통증학회 · The Korean Journal of Pain2024 · 제37권 제2호

이 간행물의 다른 논문 (9건)

Opioid: toward an effective strategy for better useYeon-Dong Kimpp. 67-68Analgesic effects of eucalyptus essential oil in miceGeun Hee Seol, Min Sun Kim, Sun Seek Min, Junbum Parkpp. 79-86Effect of sec-O-glucosylhamaudol on mechanical allodynia in a rat model of postoperative painHyun Song, Seon-Hee Oh, Gi-Ho Koh, Myung Ha Yoon, Sang Hun Kim, Kyung Joon Lim, Ki Tae Jungpp. 87-96Low-dose intravenous ketamine versus intravenous ketorolac in pain control in patients with acute renal colic in an emergency setting: a double-blind randomized clinical trialAlireza Baratloo, Fatemeh Rasooli, Arash Safaie, Mozhgan Farmahini-Farahani, Mehran Sotoodehniapp. 97-104Small dose of naloxone as an adjuvant to bupivacaine in intrapleural infiltration after thoracotomy surgery: a prospective, controlled studyAmany Faheem Omara, Asmaa Fawzy Amerpp. 105-112
원문 보기